Skip to content

Maternal and Neonatal Outcome in Severe Preeclampsia

Maternal and Neonatal Outcome in Severe Preeclamptic Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04126122
Enrollment
100
Registered
2019-10-15
Start date
2019-02-10
Completion date
2020-02-01
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Brief summary

In normal pregnancy the spiral arteries in the placental bed are invaded by trophoblast, which becomes incorporated into the vessel wall and replaces the endothelium, muscular layer and neural tissue

Detailed description

Preeclampsia is considered severe if one or more of the following: 1. Blood pressure of 160mmHg systolic or high or 110mmHg diastolic or high on two occasions at least 6 hours a part while the patient on bed rest. 2. Proteinuria of 0.3gm. or high in 24 hours urine specimen or +1 or great on two random urine samples collected at least 4 hours apart. 3. Oliguria of less than 500ml in 24 hours. 4. Cerebral or visual disturbance. 5. Pulmonary edema or cyanosis.

Interventions

DIAGNOSTIC_TESTUltrasonography to assess fetus and mother

to assess fetal growth and maternal outcome

Sponsors

Cairo University
CollaboratorOTHER
Aljazeera Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 42 Years
Healthy volunteers
Yes

Inclusion criteria

* • All women with severe preeclampsia

Exclusion criteria

* • History of epilepsy. * Patients with chronic hypertension. * Patients with renal disease.

Design outcomes

Primary

MeasureTime frameDescription
The number of women who will develop adverse outcomewithin 5 monthsThe women with preeclampsia who will develop eclampsia or pulmonaryb edema

Countries

Egypt

Contacts

Primary ContactMahmoud Alalfy, PhD
mahmoudalalfy@ymail.com01002611058

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026